Guardant Health, Inc. - GH STOCK NEWS

Guardant Health (NASDAQ: GH) reported preliminary, unaudited results for 2022, showing a revenue increase of 20% to between $447 million and $450 million. Clinical and biopharma test volumes rose by 42% and 40%, with 124,800 and 26,000 tests respectively. For Q4 2022, revenue was projected between $124 million and $127 million, up 15%-17% year-over-year. The company ended the year with $1 billion in cash and equivalents. Analysts express optimism for continued double-digit growth in 2023.

Guardant Health, a leading precision oncology company, will participate in the 41^st Annual J.P. Morgan Healthcare Conference on January 9, at 3:00 p.m. PT. The management will present and engage in a Q&A session, with a live and archived webcast available on their website. Guardant Health is known for its innovative cancer testing solutions, including Guardant360^® and Guardant Reveal™, aimed at improving patient outcomes and lowering healthcare costs. For more details, visit guardanthealth.com.

Guardant Health has partnered with Susan G. Komen to enhance breast cancer care. This collaboration aims to develop clinical studies focusing on high-risk early-stage breast cancer patients, utilizing Guardant Reveal™, a blood test for detecting minimal residual disease (MRD). By integrating input from patient advocates, the partnership seeks to create patient-centric research that informs treatment strategies. The initiative aligns with the goal of improving outcomes through personalized cancer monitoring and therapy.

Guardant Health reported promising results from the ECLIPSE study, demonstrating an 83% sensitivity and 90% specificity in detecting colorectal cancer (CRC) using its blood test. The study involved over 20,000 patients and provides a pathway for a potential FDA approval and Medicare reimbursement. Additionally, the test showed a significant increase in screening adherence, with 90% of patients completing the test compared to 43%-66% for stool tests. Guardant plans to file for premarket approval in Q1 2023.

Guardant Health has announced a collaboration with AstraZeneca to develop the Guardant360 CDx blood test as a companion diagnostic for ESR1-mutated metastatic breast cancer. This initiative is part of a strategic partnership to leverage liquid biopsy for early therapy interventions. The Guardant360 CDx test will identify patients with detectable ESR1 mutations during the SERENA-6 phase III clinical trial, evaluating camizestrant. The collaboration aims to improve patient outcomes through early detection and intervention.

Guardant Health (Nasdaq: GH) has announced that new data from its blood tests will be presented at the 2022 San Antonio Breast Cancer Symposium from December 6-10. The presentations will showcase the Guardant360® blood test and the GuardantINFORM™ dataset, focusing on critical biomarkers and treatment patterns in advanced breast cancer. Guardant aims to demonstrate the utility of its tests in enhancing understanding of biomarker targets and therapy responses, potentially leading to improved patient outcomes.

Guardant Health, Inc. (Nasdaq: GH) reported its Q3 2022 financial results, achieving $117.4 million in revenue, a 24% year-over-year increase. Clinical testing volumes surged 42% and biopharma sample volumes rose 40% compared to Q3 2021. Despite this growth, the company experienced a net loss of $162 million, a significant increase from $107.5 million the previous year. Operating expenses also rose 29% to $221.5 million. Due to ongoing challenges, the revenue guidance for 2022 has been revised down to $440-$450 million.

Guardant Health, Inc. (NASDAQ: GH) announced it will release its third quarter 2022 financial results on November 3, 2022, after market close. The company will host a webcast conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can listen live through the company's website, with an archived replay available post-event. Guardant Health focuses on precision oncology and offers a variety of proprietary tests aimed at improving patient outcomes and reducing healthcare costs.

Guardant Health (NASDAQ: GH) has launched GuardantINFINITY™, a next-generation liquid biopsy assay that enhances tumor analysis by combining over 800 gene panel insights with exome-wide methylation detection. This innovative platform allows researchers to gain comprehensive insights into tumor biology and patient immune responses through a simple blood draw, eliminating the need for further sample collection. The assay supports various applications, including therapy selection and monitoring, marking a significant advancement in precision oncology.